Why the study?
No-reflow during angioplasty in STEMI carries a grave prognosis with adverse cardiac outcomes, and various drugs have been evaluated to manage this state.
Does catheter-directed intracoronary thrombolysis improve myocardial reperfusion and reduce thrombus burden in STEMI patients experiencing no-reflow during percutaneous transcoronary angioplasty?
Does catheter-directed intracoronary thrombolysis improve myocardial reperfusion and reduce thrombus burden in STEMI patients experiencing no-reflow during percutaneous transcoronary angioplasty?
Catheter-directed intracoronary thrombolysis may be a safe and effective strategy to manage the no-reflow phenomenon during primary PCI for STEMI.
May aid refractory no-reflow management; leaves open efficacy confirmation in randomized STEMI trials.
Catheter-directed ICT is safe and effective in reducing thrombus burden, thus improving myocardial reperfusion in STEMI. This condition has a grave prognosis and can lead to adverse cardiac outcomes. There are many drugs that have been tried to manage no reflow. The use of ICT to treat no-reflow state can be life saving with minimal systemic side effects.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: